At IMARC, we pride ourselves on being trusted advisors. It’s our greatest privilege to support
clinical research sponsors and help them earn approval to bring their devices to market.
Read more: https://www.massdevice.com/the-most-popular-clinical-research-resources-from-2018/
2018 was a banner year for biosimilars, with the number of FDA-aproved biosimilar products nearly
doubling, and with major policy,
business, and regulatory developments that moved the biosimilars marketplace forward.
Read more at: https://www.ajmc.com/newsroom/the-key-biosimilars-developments-of-2018
Once again, it’s time to reflect on the preceding 12 months. Despite the 2025 deadline for
effective therapy that has been set by the National Alzheimer’s Plan and the World Dementia
Council, 2018 brought no drug approvals or Phase 3 breakthroughs.
Read more at: https://www.alzforum.org/news/search-news/2018-year-research
There were a variety of developments in the biosimilars space in 2018, and our expert contributors
responded to those changes with in-depth insights that reflected the complexity of the biosimilars
Read more at: https://www.centerforbiosimilars.com/news/the-mostread-contributor-articles-of-2018
Here are our picks for the top-five most significant U.S. biosimilar market developments in 2018:
Read more at: https://www.jdsupra.com/legalnews/year-in-review-the-top-five-u-s-22499/